Selected article for: "cell cross reactivity and cross reactivity"

Author: Kim, Sung-Kwon; Cornberg, Markus; Wang, Xiaoting Z.; Chen, Hong D.; Selin, Liisa K.; Welsh, Raymond M.
Title: Private specificities of CD8 T cell responses control patterns of heterologous immunity
  • Document date: 2005_2_21
  • ID: 55gi6gyx_3
    Snippet: Under conditions of heterologous immunity, T cell responses are sometimes uniformly directed against strongly cross-reactive epitopes, such as between LCMV and PV. However, in other cases, patterns of heterologous immunity and T cell cross-reactivity may be variable, such as between LCMV and vaccinia virus (VV). A history of an LCMV infection protects mice against VV, reducing VV titers 10-100-fold by day 3 after infection, and dramatically chang.....
    Document: Under conditions of heterologous immunity, T cell responses are sometimes uniformly directed against strongly cross-reactive epitopes, such as between LCMV and PV. However, in other cases, patterns of heterologous immunity and T cell cross-reactivity may be variable, such as between LCMV and vaccinia virus (VV). A history of an LCMV infection protects mice against VV, reducing VV titers 10-100-fold by day 3 after infection, and dramatically changing the T cell-dependent immunopathology (1, 3) . Adoptive transfer studies indicated that LCMV-immune CD4 and CD8 T cells provided heterologous immunity in this system (1) . Ironically, a history of a VV infection has little effect on immunity to LCMV (1) . VV induces the proliferation of some LCMV-specific memory T cells, but LCMV does not induce detectable proliferation of VV-specific memory T cells (4) . A possible explanation to this enigma is that VV is a virus that encodes Ͼ 200 proteins and perhaps Ͼ 1,000 T cell epitopes with the capacity to trigger memory T cells present at sufficient frequencies. In contrast, LCMV encodes only four proteins. Thus, it seems that the many potential epitopes encoded by VV would more likely stimulate some T cells in an LCMV-specific memory pool than would the much more limited number of LCMV epitopes stimulating a VV-immune pool.

    Search related documents:
    Co phrase search for related documents
    • cell cross reactivity and heterologous immunity: 1, 2, 3, 4, 5, 6, 7
    • cell cross reactivity and heterologous immunity provide: 1, 2
    • cell cross reactivity and LCMV epitope: 1, 2, 3
    • cell cross reactivity and LCMV infection: 1, 2
    • cell cross reactivity and limited number: 1, 2
    • cell dependent immunopathology and cross reactivity: 1
    • cell dependent immunopathology and heterologous immunity: 1
    • cell dependent immunopathology and LCMV epitope: 1
    • cell dependent immunopathology and LCMV infection: 1, 2
    • cell epitope and cross reactivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell epitope and heterologous immunity: 1, 2, 3, 4
    • cell epitope and LCMV epitope: 1, 2, 3, 4, 5, 6, 7, 8
    • cell epitope and LCMV infection: 1, 2, 3, 4
    • cell epitope and LCMV specific memory pool: 1
    • cell epitope and limited number: 1, 2
    • cell response and cross reactivity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell response and detectable proliferation: 1
    • cell response and heterologous immunity: 1, 2, 3, 4
    • cell response and LCMV epitope: 1, 2, 3, 4, 5, 6, 7